Nautilus Capital Surpluse from 2010 to 2025
| NAUT Stock | USD 1.71 0.06 3.39% |
Capital Surpluse | First Reported 2010-12-31 | Previous Quarter 523.6 M | Current Value 331.9 M | Quarterly Volatility 212 M |
Check Nautilus Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nautilus Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 7 M or Selling General Administrative of 25.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.12. Nautilus financial statements analysis is a perfect complement when working with Nautilus Biotechnology Valuation or Volatility modules.
Nautilus | Capital Surpluse |
Latest Nautilus Biotechnology's Capital Surpluse Growth Pattern
Below is the plot of the Capital Surpluse of Nautilus Biotechnology over the last few years. It is Nautilus Biotechnology's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nautilus Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Capital Surpluse | 10 Years Trend |
|
Capital Surpluse |
| Timeline |
Nautilus Capital Surpluse Regression Statistics
| Arithmetic Mean | 141,959,207 | |
| Geometric Mean | 21,652,186 | |
| Coefficient Of Variation | 149.36 | |
| Mean Deviation | 187,600,376 | |
| Median | 5,522,570 | |
| Standard Deviation | 212,035,862 | |
| Sample Variance | 44959.2T | |
| Range | 518.1M | |
| R-Value | 0.78 | |
| Mean Square Error | 18671.1T | |
| R-Squared | 0.61 | |
| Significance | 0.0003 | |
| Slope | 34,852,325 | |
| Total Sum of Squares | 674388.1T |
Nautilus Capital Surpluse History
About Nautilus Biotechnology Financial Statements
Nautilus Biotechnology shareholders use historical fundamental indicators, such as Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Nautilus Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Nautilus Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Nautilus Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Surpluse | 523.6 M | 331.9 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.